ACM
XLRN

Asymmetry Capital Management’s Acceleron Pharma XLRN Stock Holding History

Asymmetry Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-47,453
Closed -$1.88M – 43
2019
Q3 		$1.88M Sell
47,453
-35,020
-42% -$1.52M 4.02% 12
2019
Q2 		$3.39M Buy
82,473
+52,348
+174% +$2.17M 1.83% 20
2019
Q1 		$1.4M Buy
30,125
+11,561
+62% +$508K 2.34% 15
2018
Q4 		$808K Sell
18,564
-21,348
-53% -$1.07M 2.23% 15
2018
Q3 		$2.28M Buy
39,912
+17,354
+77% +$853K 2.11% 21
2018
Q2 		$1.09M Buy
+22,558
New +$822K 1.08% 30

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Asymmetry Capital Management's XLRN Position: Q4 2019 in Review

Asymmetry Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2019, closing a stake of 47,453 shares — an estimated $1.88M sold.

Asymmetry Capital Management first reported a position in XLRN in Q2 2018 and held it in 6 quarters. The position peaked at $3.39M in Q2 2019. 183 funds tracked by Wall St. Rank hold XLRN as of Q4 2019.

  • Asymmetry Capital Management reported no remaining Acceleron Pharma position as of Q4 2019 after selling out during the quarter.
  • Asymmetry Capital Management sold 47,453 Acceleron Pharma shares in Q4 2019, an estimated $1.88M.
  • Asymmetry Capital Management first reported a position in Acceleron Pharma in Q2 2018 and held it in 6 quarters.
  • Asymmetry Capital Management's Acceleron Pharma position peaked at $3.39M in Q2 2019.
  • 183 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2019.

Based on Asymmetry Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.